• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>iShares Nasdaq Biotechnology

iShares Nasdaq Biotechnology

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Bull case strengthens as summer cross currents -2-

    Bull case strengthens as summer cross currents -2-

  2. UPDATE: 'Smart beta' indexed ETFs sure attract a lot of dumb money

    UPDATE: 'Smart beta' indexed ETFs sure attract a lot of dumb money

  3. UPDATE: Charting the U.S. markets' technical -2-

    UPDATE: Charting the U.S. markets' technical -2-

  4. Charting the U.S. markets' technical cross -2-

    Charting the U.S. markets' technical cross -2-

  5. An ETF for This Lagging Sector

    Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.

  6. Where Are the Opportunities in U.S. Health Care?

    As the sector has continued to best the broader market, a look both at the dynamics that would drive further outperformance by the sector and at funds that investors can use to tap those themes.

  7. Why the Short-Term Tumult?

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  8. Analytical and Independent

    Jerry Slusiewicz depends on his own analysis and risk-management philosophy to keep client portfolios in order.

  9. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.